Publications by authors named "O Bolte"
Article Synopsis
- Between July 2000 and June 2003, 21 patients with high-risk acute myeloid leukemia and related conditions underwent treatment with an 188-Re labeled anti-CD66 antibody as part of their stem cell transplant preparation.
- The patients received standard full-dose or reduced intensity conditioning regimens, and most were grafted with unmanipulated allogeneic stem cells from either alternative or HLA-identical family donors.
- The study found a 43% disease-free survival rate after a median follow-up of 42 months, with mild late organ toxicity, but a significant treatment-related mortality of 28.6%.
Article Synopsis
- Axitinib is a targeted oral medication shown to be effective in treating metastatic renal-cell cancer in patients previously treated with cytokines, with a 44.2% objective response rate.
- The study involved 52 patients, tracking primary outcomes like response rate and secondary outcomes such as duration of response and overall survival, revealing a median response duration of 23 months.
- While there were significant benefits, adverse side effects, particularly treatment-related hypertension, were common but manageable with medication.
Purpose: The objective of this study was to determine and verify the stability of 211At-labelled antibodies under physiological conditions and their specific cell-binding capacity for selected epitopes, in order to evaluate the potential of 211At for alpha-radioimmunotherapy.
Methods: 211At was produced at the department's cyclotron and was linked via the intermediate 3-211At-succinimidyl-benzoate (SAB) to the antineoplastic antibodies rituximab, gemtuzumab and gemtuzumab ozogamicin. The stability of the labelled antibodies was determined in serum for 21 h.
Aviscumine is a ribosome-inactivating protein with potent antitumour activity in vitro and in vivo and is an Escherichia coli-derived recombinant counterpart of natural mistletoe lectin-I. The current study was performed to determine the safety profile, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of a prolonged infusion of aviscumine in cancer patients. Aviscumine was given once weekly as a 24 h central intravenous infusion in patients with advanced, refractory progressive solid malignant tumours.
View Article and Find Full Text PDFBackground: Testicular cancer has a favorable prognosis in the majority of patients due to the excellent susceptibility to chemotherapy with cisplatin, etoposide and bleomycin (BEP), which is commonly administered over 3-4 cycles of treatment.
Case Report: A 22-year-old male failed to achieve complete response after unconventional treatment with 6 courses of BEP for intermediate-risk metastasized testicular cancer. The patient developed chemotherapy-induced digital necrosis and substantial loss of digital function after this excessive treatment.